Coronavirus Outbreak: USFDA approves albuterol sulfate-based inhaler as demand increases due to COVID-19 pandemic

The generic version of the inhaler will be manufactured by Indian drugmaker Cipla Ltd.

FP Trending April 09, 2020 12:36:21 IST
Coronavirus Outbreak: USFDA approves albuterol sulfate-based inhaler as demand increases due to COVID-19 pandemic

The US Food and Drug Administration (USFDA) has given its nod to the first generic of a commonly used albuterol sulfate-based inhaler.

Coronavirus Outbreak USFDA approves albuterol sulfatebased inhaler as demand increases due to COVID19 pandemic

Representational image. Image by HenkieTenk from Pixabay.

The demand for albuterol products has seen a spike as people infected with novel coronavirus suffer from breathing difficulties.

“The FDA recognizes the increased demand for albuterol products during the novel coronavirus pandemic,” said FDA Commissioner Stephen Hahn. He added that they are committed to providing medical products to cater to the needs of the public.

The generic version of the inhaler will be manufactured by Indian drugmaker Cipla Ltd. The albuterol sulfate-based inhaler is used in the treatment of bronchospasm, a condition in which patients face difficulty in breathing.

Last month, the drug regulator had put out a revised draft for proposed generic albuterol sulfate metered dose inhalers.

In its press release, USFDA also highlighted the common side-effects associated with albuterol inhalers.

Click here for Coronavirus Outbreak LIVE Updates

Upper respiratory tract infection, rhinitis, nausea, vomiting, rapid heart rate (tachycardia), tremor and nervousness are the most common side-effects, it said.

The novel coronavirus has infected lakhs of people globally and claimed the lives of thousands. It has also brought financial activities across the world to a grinding halt.

The symptoms of coronavirus infection include fever, coughing and breathing difficulties.

Updated Date:

also read

Dengue cases climb in West Bengal, 840 new infections in run-up to festival
India

Dengue cases climb in West Bengal, 840 new infections in run-up to festival

Most of the cases have been reported from North 24 Parganas, Howrah, Kolkata, Hooghly, Murshidabad, South 24 Parganas, Jalpaiguri and Darjeeling districts

COVID-19: Active Covid cases in India rise to 46,342
Health

COVID-19: Active Covid cases in India rise to 46,342

The active cases comprise 0.10 per cent of the total infections, while the national COVID-19 recovery rate increased to 98.71 per cent.

WHO no longer recommends use of 2 Covid-19 antibody therapies: BMJ
World

WHO no longer recommends use of 2 Covid-19 antibody therapies: BMJ

The “strong” recommendation replaces previous conditional recommendations for their use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as Omicron